Eye on Emerging Data on Small Molecule Inhibitors in IBD
Eye on Emerging Data on Small Molecule Inhibitors in IBD is organized by Medscape, LLC.
CME / ABIM MOC / CE Released: 1/7/2021
Valid for credit through: 1/7/2022
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Current treatments for more severe inflammatory bowel disease (IBD) are ineffective in a large proportion of patients. The goal of this initiative is to raise awareness of and educate on the new and emerging targeted small molecules for the treatment of patients with IBD.
Upon completion of this activity, participants will:
• Recent clinical data on emerging agents for moderate to severe IBD
• The mechanism of action (MOA) of emerging treatments for moderate to severe IBD
- CME : 0.5
- MOC : 0.5
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine